·糖尿病与并发症·糖尿病新世界2024年2月DOI：10.16658/j.cnki.1672-4062.2024.04.171胰激肽原酶肠溶片联合达格列净治疗糖尿病肾病的疗效分析崔韶华栖霞市人民医院肾内科，山东烟台265300[摘要]目的探讨胰激肽原酶肠溶片联合达格列净治疗糖尿病肾病的疗效。方法选取2021年1月—2023年6月栖霞市人民医院收治的80例糖尿病肾病患者为研究对象，以随机数表法将其分为对照组及研究组，各40例。研究组接受胰激肽原酶肠溶片联合达格列净疗法治疗，对照组仅接受达格列净治疗。比较两组患者治疗前后的肾功能指标、血糖指标、炎症指标及生存质量。结果治疗前，两组患者肾功能、血糖、炎症指标及生存质量评分相比，差异无统计学意义（P均>0.05）。治疗后，两组患者血肌酐、24ｈ尿蛋白定量及血糖、炎症指标均下降，且研究组较对照组更低，差异有统计学意义（P均<0.05）。两组患者的血白蛋白、健康调查简表评分和糖尿病控制状况量表评分较治疗前升高，且研究组高于对照组，差异有统计学意义（P均<0.05）。结论胰激肽原酶肠溶片联合达格列净疗法能够有效改善糖尿病肾病患者的肾功能、血糖相关指标，减轻炎症反应，从而改善患者的肾脏预后，提高患者生存质量。[关键词]胰激肽原酶肠溶片；达格列净；糖尿病肾病；肾功能；血糖[中图分类号]R4文献[标识码]A文章编号[]1672-4062（2024）02（b）-0171-04TherapeuticEffectofPancreaticKallidinogenaseEntericCoatedTabletsCombinedwithDapagliflozinonDiabetesNephropathyCUIShaohuaDepartmentofNephrology,QixiaPeople'sHospital,Yantai,ShandongProvince,265300China[Abstract]ObjectiveToinvestigatetheeffectofpancreatickininogenaseentericcoatedtabletscombinedwithdapa⁃gliflozininthetreatmentofdiabeticnephropathy.MethodsAtotalofeightypatientswithdiabeticnephropathyadmit⁃tedtoQixiaPeople'sHospitalfrom2021JanuarytoJune2023wereselectedasthestudyobjects,andweredividedintocontrolgroupandstudygroupbyrandomnumbertablemethod,withfortycasesineachgroup.Thestudygroupreceivedpancreatickininogenaseentericcoatedtabletscombinedwithdapagliflozintherapy,whilethecontrolgroupreceivedonlydapagliflozintherapy.Renalfunctionindexes,bloodglucoseindexes,inflammationindexesandqualityoflifewerecomparedbetweenthetwogroupsbeforeandafterResultstreatment.Beforetreatment,therewerenosig⁃nificantdifferenceinrenalfunction,bloodglucose,inflammationindexandqualityoflifescorebetweentwogroups(allP>0.05).Aftertreatment,serumcreatinine,24hurinaryproteinquantity,bloodglucoseandinflammationindexeswerealldecreasedintwogroups,andthoseofthestudygroupwerelowerthanthecontrolgroup,andthedifferenceswerestatisticallysignificantP<0.05).(allThelevelsofbloodalbuminandscoresofMOSItemShortFromHealthSur⁃veyandControlStatusScaleforDiabetiesintwogroupsaf